James Caggianoformer CEO at Dendreon
With nearly 30 years of experience in the biotech/pharmaceutical and medical device industries, Jim Caggiano is committed to advancing therapeutic options that improve the lives of patients. Having spent his career focused on areas of medicine where few or no effective options exist, including urology, gynecology and cardiology, he most recently served as chief executive officer of Dendreon Pharmaceuticals LLC.
A seasoned and dynamic leader, Caggiano has a proven track record of creating value in turnaround situations and managing business transitions.
He successfully directed the divestiture of Allergan’s LAP-BAND to Apollo Endosurgery in 2013, and later developed and implemented the strategy for Dendreon’s sale to Sanpower Group in 2017.
After the acquisition of Dendreon out of bankruptcy by Valeant for $415M in 2014, Caggiano was able to turn the enterprise to profitability and subsequently sold it to Sanpower holding for $820M in 2017.
He is credited with Dendreon’s resurgence as an exciting and growing enterprise aimed at bringing PROVENGE® (sipuleucel-T) – the company’s flagship product and the only immunotherapy treatment option for men with advanced prostate cancer – to the nearly 50,000 men who could benefit from this life-extending treatment.
Earlier in his career, Caggiano held senior roles at Allergan, Inc., Abbott Laboratories and TAP Pharmaceuticals, where he led sales and marketing functions for Lupron®, a prostate cancer treatment.
Caggiano received a B.S. in agricultural economics (business) from Cornell University and an M.B.A. from the Kellogg School of Management at Northwestern University. Prior to entering industry, Caggiano served as an officer in the Armor Branch of the United States Army.